KAIST Discovers Key to Immunotherapy for Brain Tumors
KAIST researchers have discovered that B cells in tumor-draining lymph nodes play a critical role in the effectiveness of anti-CTLA-4 immunotherapy for brain tumors. This finding challenges the traditional focus on T cells and suggests new strategies for treating aggressive glioblastomas.
Researchers have uncovered a clue to why immune checkpoint inhibitors - cancer therapies that release the immune "brakes" exploited by tumors to evade attack - show limited efficacy in some brain tumors. A KAIST research team found that B cell and antibody responses initiated in tumor-draining lymph nodes, rather than T cells alone, are critical to the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in